tiprankstipranks
Trending News
More News >
Regeneron Pharmaceuticals (DE:RGO)
:RGO
Germany Market
Advertisement

Regeneron (RGO) Stock Forecast & Price Target

Compare
2 Followers
See the Price Targets and Ratings of:

RGO Analyst Ratings

Strong Buy
21Ratings
Strong Buy
17 Buy
3 Hold
1 Sell
Based on 21 analysts giving stock ratings to
Regeneron
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RGO Stock 12 Month Forecast

Average Price Target

€630.34
▲(24.72% Upside)
Based on 21 Wall Street analysts offering 12 month price targets for Regeneron in the last 3 months. The average price target is €630.34 with a high forecast of €766.60 and a low forecast of €467.71. The average price target represents a 24.72% change from the last price of €505.40.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"432":"€432","560":"€560","688":"€688","816":"€816","944":"€944"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":766.6016602,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€766.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":630.3446752258,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€630.34</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":467.71314774,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€467.71</span>\n  </div></div>","useHTML":true}}],"tickPositions":[432,560,688,816,944],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,523.2,541.9232046307693,560.6464092615385,579.3696138923077,598.092818523077,616.8160231538461,635.5392277846154,654.2624324153846,672.9856370461539,691.708841676923,710.4320463076923,729.1552509384614,747.8784555692307,{"y":766.6016602,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,523.2,531.4418980942924,539.6837961885847,547.925694282877,556.1675923771693,564.4094904714616,572.6513885657539,580.8932866600461,589.1351847543384,597.3770828486307,605.618980942923,613.8608790372153,622.1027771315077,{"y":630.3446752258,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,523.2,518.9317805953847,514.6635611907693,510.3953417861539,506.12712238153847,501.8589029769231,497.59068357230774,493.3224641676923,489.05424476307695,484.78602535846153,480.51780595384616,476.2495865492308,471.9813671446154,{"y":467.71314774,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":943.317,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":778.829,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":720.083,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":673.883,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":652.575,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":670.971,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":579.647,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":494.105,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":433.434,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":441.621,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":469.279,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":500,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":523.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€766.60Average Price Target€630.34Lowest Price Target€467.71
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on DE:RGO
Bank of America Securities
Bank of America Securities
€466.34
Sell
-7.73%
Downside
Reiterated
10/15/25
Regeneron Faces Declining Eylea Sales and Medicare Risks, Justifying Sell Rating
Wells Fargo Analyst forecast on DE:RGO
Wells Fargo
Wells Fargo
€498.12
Hold
-1.44%
Downside
Reiterated
10/14/25
Wells Fargo Sticks to Its Hold Rating for Regeneron (REGN)
Citi
€566.82
Buy
12.15%
Upside
Reiterated
10/13/25
Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Sysmex (SSMXF)
Canaccord Genuity Analyst forecast on DE:RGO
Canaccord Genuity
Canaccord Genuity
€730
Buy
44.44%
Upside
Reiterated
10/13/25
Canaccord Genuity Reaffirms Their Buy Rating on Regeneron (REGN)
Morgan Stanley Analyst forecast on DE:RGO
Morgan Stanley
Morgan Stanley
€653.56€649.27
Buy
28.47%
Upside
Reiterated
10/10/25
Regeneron price target lowered to $756 from $761 at Morgan StanleyRegeneron price target lowered to $756 from $761 at Morgan Stanley
Cantor Fitzgerald Analyst forecast on DE:RGO
Cantor Fitzgerald
Cantor Fitzgerald
€582.28
Buy
15.21%
Upside
Reiterated
10/09/25
Cantor Fitzgerald Keeps Their Buy Rating on Regeneron (REGN)
RBC Capital Analyst forecast on DE:RGO
RBC Capital
RBC Capital
€596.88€604.61
Hold
19.63%
Upside
Reiterated
10/08/25
RBC Capital Keeps Their Hold Rating on Regeneron (REGN)
J.P. Morgan Analyst forecast on DE:RGO
J.P. Morgan
J.P. Morgan
€687.06
Buy
35.94%
Upside
Reiterated
10/03/25
Leerink Partners Analyst forecast on DE:RGO
Leerink Partners
Leerink Partners
€553.94
Buy
9.60%
Upside
Reiterated
10/01/25
Regeneron (REGN) Gets a Buy from Leerink Partners
Bernstein
€670.74
Buy
32.71%
Upside
Reiterated
09/26/25
Regeneron (REGN) Gets a Buy from Bernstein
Raymond James Analyst forecast on DE:RGO
Raymond James
Raymond James
€577.99
Buy
14.36%
Upside
Reiterated
09/26/25
Raymond James Remains a Buy on Regeneron (REGN)
BMO Capital Analyst forecast on DE:RGO
BMO Capital
BMO Capital
€549.64
Buy
8.75%
Upside
Reiterated
09/08/25
Buy Rating for Regeneron Amid Promising Allergy Treatment Trials and Strong Oncology Prospects
Evercore ISI Analyst forecast on DE:RGO
Evercore ISI
Evercore ISI
€644.11
Buy
27.45%
Upside
Reiterated
08/27/25
Regeneron (REGN) Gets a Buy from Evercore ISI
UBS
€511
Hold
1.11%
Upside
Reiterated
08/27/25
UBS Reaffirms Their Hold Rating on Regeneron (REGN)
Jefferies Analyst forecast on DE:RGO
Jefferies
Jefferies
€698.22€713.68
Buy
41.21%
Upside
Reiterated
08/27/25
Regeneron (REGN) Receives a Buy from Jefferies
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on DE:RGO
Bank of America Securities
Bank of America Securities
€466.34
Sell
-7.73%
Downside
Reiterated
10/15/25
Regeneron Faces Declining Eylea Sales and Medicare Risks, Justifying Sell Rating
Wells Fargo Analyst forecast on DE:RGO
Wells Fargo
Wells Fargo
€498.12
Hold
-1.44%
Downside
Reiterated
10/14/25
Wells Fargo Sticks to Its Hold Rating for Regeneron (REGN)
Citi
€566.82
Buy
12.15%
Upside
Reiterated
10/13/25
Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Sysmex (SSMXF)
Canaccord Genuity Analyst forecast on DE:RGO
Canaccord Genuity
Canaccord Genuity
€730
Buy
44.44%
Upside
Reiterated
10/13/25
Canaccord Genuity Reaffirms Their Buy Rating on Regeneron (REGN)
Morgan Stanley Analyst forecast on DE:RGO
Morgan Stanley
Morgan Stanley
€653.56€649.27
Buy
28.47%
Upside
Reiterated
10/10/25
Regeneron price target lowered to $756 from $761 at Morgan StanleyRegeneron price target lowered to $756 from $761 at Morgan Stanley
Cantor Fitzgerald Analyst forecast on DE:RGO
Cantor Fitzgerald
Cantor Fitzgerald
€582.28
Buy
15.21%
Upside
Reiterated
10/09/25
Cantor Fitzgerald Keeps Their Buy Rating on Regeneron (REGN)
RBC Capital Analyst forecast on DE:RGO
RBC Capital
RBC Capital
€596.88€604.61
Hold
19.63%
Upside
Reiterated
10/08/25
RBC Capital Keeps Their Hold Rating on Regeneron (REGN)
J.P. Morgan Analyst forecast on DE:RGO
J.P. Morgan
J.P. Morgan
€687.06
Buy
35.94%
Upside
Reiterated
10/03/25
Leerink Partners Analyst forecast on DE:RGO
Leerink Partners
Leerink Partners
€553.94
Buy
9.60%
Upside
Reiterated
10/01/25
Regeneron (REGN) Gets a Buy from Leerink Partners
Bernstein
€670.74
Buy
32.71%
Upside
Reiterated
09/26/25
Regeneron (REGN) Gets a Buy from Bernstein
Raymond James Analyst forecast on DE:RGO
Raymond James
Raymond James
€577.99
Buy
14.36%
Upside
Reiterated
09/26/25
Raymond James Remains a Buy on Regeneron (REGN)
BMO Capital Analyst forecast on DE:RGO
BMO Capital
BMO Capital
€549.64
Buy
8.75%
Upside
Reiterated
09/08/25
Buy Rating for Regeneron Amid Promising Allergy Treatment Trials and Strong Oncology Prospects
Evercore ISI Analyst forecast on DE:RGO
Evercore ISI
Evercore ISI
€644.11
Buy
27.45%
Upside
Reiterated
08/27/25
Regeneron (REGN) Gets a Buy from Evercore ISI
UBS
€511
Hold
1.11%
Upside
Reiterated
08/27/25
UBS Reaffirms Their Hold Rating on Regeneron (REGN)
Jefferies Analyst forecast on DE:RGO
Jefferies
Jefferies
€698.22€713.68
Buy
41.21%
Upside
Reiterated
08/27/25
Regeneron (REGN) Receives a Buy from Jefferies
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Regeneron

1 Month
xxx
Success Rate
12/20 ratings generated profit
60%
Average Return
+0.55%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +0.55% per trade.
3 Months
xxx
Success Rate
17/30 ratings generated profit
57%
Average Return
-0.24%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 56.67% of your transactions generating a profit, with an average return of -0.24% per trade.
1 Year
David RisingerLeerink Partners
Success Rate
17/25 ratings generated profit
68%
Average Return
+10.61%
reiterated a buy rating 24 days ago
Copying David Risinger's trades and holding each position for 1 Year would result in 68.00% of your transactions generating a profit, with an average return of +10.61% per trade.
2 Years
xxx
Success Rate
17/25 ratings generated profit
68%
Average Return
+11.53%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 68.00% of your transactions generating a profit, with an average return of +11.53% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RGO Analyst Recommendation Trends

Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
32
14
9
2
3
Buy
33
38
51
55
46
Hold
12
12
11
8
7
Sell
6
3
3
2
2
Strong Sell
0
0
0
0
0
total
83
67
74
67
58
In the current month, RGO has received 49 Buy Ratings, 7 Hold Ratings, and 2 Sell Ratings. RGO average Analyst price target in the past 3 months is 630.34.
Each month's total comprises the sum of three months' worth of ratings.

RGO Financial Forecast

RGO Earnings Forecast

Next quarter’s earnings estimate for RGO is €8.30 with a range of €6.56 to €9.11. The previous quarter’s EPS was €11.11. RGO beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year RGO has Preformed in-line its overall industry.
Next quarter’s earnings estimate for RGO is €8.30 with a range of €6.56 to €9.11. The previous quarter’s EPS was €11.11. RGO beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year RGO has Preformed in-line its overall industry.

RGO Sales Forecast

Next quarter’s sales forecast for RGO is €3.09B with a range of €3.01B to €3.27B. The previous quarter’s sales results were €3.17B. RGO beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year RGO has Preformed in-line its overall industry.
Next quarter’s sales forecast for RGO is €3.09B with a range of €3.01B to €3.27B. The previous quarter’s sales results were €3.17B. RGO beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year RGO has Preformed in-line its overall industry.

RGO Stock Forecast FAQ

What is DE:RGO’s average 12-month price target, according to analysts?
Based on analyst ratings, Regeneron Pharmaceuticals’s 12-month average price target is 630.34.
    What is DE:RGO’s upside potential, based on the analysts’ average price target?
    Regeneron Pharmaceuticals has 24.72% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Regeneron Pharmaceuticals a Buy, Sell or Hold?
          Regeneron Pharmaceuticals has a consensus rating of Strong Buy, which is based on 17 buy ratings, 3 hold ratings and 1 sell ratings.
            What is Regeneron Pharmaceuticals’s share price target?
            The average share price target for Regeneron Pharmaceuticals is 630.34. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €766.60 ,and the lowest forecast is €467.71. The average share price target represents 24.72% Increase from the current price of €505.4.
              What do analysts say about Regeneron Pharmaceuticals?
              Regeneron Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.
                How can I buy shares of Regeneron Pharmaceuticals?
                To buy shares of DE:RGO, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis